GoKawiilUS Cancer Patients Turn to Shanghai for Cheaper CAR-T Immunotherapy
American cancer patients are increasingly traveling to China for CAR-T cell therapy, a personalized immunotherapy that reengineers a patient's white blood cells to fight cancer. The Wall Street Journal reports that Chinese providers, having scaled up production, now offer the treatment for $150,000 to $230,000 versus $550,000 to $850,000 in the US, with faster turnaround and included follow-up care.